Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Good T Cells Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, yet they are contained within 1 distinct art unit. This concentration in 1 distinct art unit suggests a consistent technical focus for the company's current prosecution efforts, even as different individuals review the applications. The presence of different examiners indicates that while the technical group is the same, the specific review styles may vary between the matters.
REDDIG, PETER J is the busiest examiner for this portfolio, with 1 pending action under review. This workload is part of the 2 total pending office actions for the company. Since there are 2 distinct examiners but only 1 distinct art unit, the prosecution strategy involves navigating the specific standards of the Biotechnology & Pharmaceuticals area while managing interactions with the assigned staff. The 1 pending action assigned to REDDIG, PETER J reflects the distributed nature of the total actions across the available examiner pool.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| HINES, JANA A | 1 | 53.0% | +39.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 5d |
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 5d |
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | — | §102§112 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 1645 | §102§103§112 | Final Rejection | 5d | Pending | Apr 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial